featured
Asciminib vs Bosutinib in CML After Two or More Prior TKIs
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Blood 2021 Nov 25;138(21)2031-2041, D Réa, MJ Mauro, C Boquimpani, Y Minami, E Lomaia, S Voloshin, A Turkina, DW Kim, JF Apperley, A Abdo, LM Fogliatto, DDH Kim, P le Coutre, S Saussele, M Annunziata, TP Hughes, N Chaudhri, K Sasaki, L Chee, V García-Gutiérrez, JE Cortes, P Aimone, A Allepuz, S Quenet, V Bédoucha, A HochhausFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.